老年房颤患者抗凝治疗暴露期与非暴露期的安全性和有效性
与非暴露期相比,抗凝暴露期与较低卒中(HR 3.07)、心肌梗死(HR 1.85)和死亡(HR 2.87)风险相关;与华法林相比,阿哌沙班非大出血风险较低(HR 0.73),利伐沙班大出血(HR 1.33)和非大出血(HR 1.29)风险较高。
要点
- 老年房颤患者非暴露于抗凝治疗时卒中、心梗和死亡风险显著升高。
- 阿哌沙班较华法林非大出血风险更低,利伐沙班大出血和非大出血风险更高。
- 临床停用抗凝前应仔细权衡风险并支持共享决策。
核心结论
- ≥75岁房颤患者非暴露于抗凝治疗增加卒中、心肌梗死和死亡风险。
- 临床医生应仔细权衡停用抗凝的风险,尤其在考虑处方精简时提供共享决策支持。
研究设计与样本
- 回顾性队列研究,使用英国临床实践研究数据链(CPRD)2013-2017年初级保健数据。
- 通过处方数据映射抗凝暴露,采用Cox回归模型估计调整后HR。
主要发现
- 与非暴露期相比,抗凝暴露期卒中风险HR 3.07(95%CI 2.39-3.93)。
- 与非暴露期相比,抗凝暴露期心肌梗死风险HR 1.85(95%CI 1.34-2.56)。
- 与非暴露期相比,抗凝暴露期死亡风险HR 2.87(95%CI 2.63-3.12)。
- 与华法林相比,阿哌沙班非大出血风险HR 0.73(95%CI 0.64-0.85)。
- 与华法林相比,利伐沙班大出血风险HR 1.33(95%CI 1.15-1.55),非大出血风险HR 1.29(95%CI 1.16-1.44)。
临床怎么用
- 对≥75岁房颤患者应避免无充分理由停用抗凝治疗。
- 选择直接口服抗凝药时需考虑不同药物出血风险差异。
- 停用抗凝前应与患者进行共享决策并仔细权衡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anticoagulation therapy reduces stroke risk in patients with atrial fibrillation (AF), but it is often underused in older populations due to concerns about bleeding. This study aimed to compare the safety and effectiveness of anticoagulation during periods of exposure and non-exposure and across different anticoagulants in people with AF aged ≥75 years. METHODS: Using UK primary care data from the Clinical Practice Research Datalink (2013-2017), a retrospective cohort study was conducted on patients newly prescribed oral anticoagulants (warfarin or direct oral anticoagulants). Exposure to anticoagulation was mapped using prescription data. Cox regression models were used to estimate adjusted HRs for stroke, bleeding, myocardial infarction, and death during periods of exposure and non-exposure and for different anticoagulants. RESULTS: Among 20 167 patients (median age 81 years), non-exposure to anticoagulation was associated with higher risks of stroke (HR 3.07, 95% CI 2.39 to 3.93), myocardial infarction (HR 1.85, 95% CI 1.34 to 2.56) and death (HR 2.87, 95% CI 2.63 to 3.12) compared with exposure. Compared with warfarin, apixaban was associated with lower risks of non-major bleeding (HR 0.73, 95% CI 0.64 to 0.85), whereas rivaroxaban was associated with higher risks of major (HR 1.33, 95% CI 1.15 to 1.55) and non-major (HR 1.29, 95% CI 1.16 to 1.44) bleeding. CONCLUSIONS: Non-exposure to anticoagulation increases the risks of stroke, myocardial infarction and death in older patients with AF. Clinicians should carefully weigh the risks of discontinuing anticoagulation and provide shared decision-making support to patients, especially when considering deprescription.
引用
- Mitchell, Watson, Welsh, et al. Safety and effectiveness of anticoagulation therapy in older people with atrial fibrillation during exposed and unexposed treatment periods. Heart. 2025. PMID: 39961639. doi:10.1136/heartjnl-2024-324763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。